Sanjivani Paranteral Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹205 Cr
- P/E
- 20.55
- ROE
- 15.73%
- Price to sales
- 2.43
- Debt to equity
- 0.30
- 52W high / low
- ₹240 / ₹129
- EBITDA margin
- 19.02%
- Net profit margin
- 9.87%
- Promoter holding
- 31.56%
- Sales (last year)
- ₹84 Cr
Incorporated in 1994, Sanjivani Parenteral Ltd is a research-based and export-oriented pharmaceutical company[1]
Guidance scorecard · Q1 FY27 call
What Sanjivani Paranteral's management guided
and where it ranks in Pharmaceuticals & Biotechnology
RevenueQ3 FY26 call
10–20%- FY '26 expected closing revenue for base business: INR 73-75 crores; target for FY '27: INR 90 crores.
- SPL Infusion Private Limited (Pune JV) expected to contribute INR 60-65 crores in FY '27.
- Base business expected to grow around 18-20% in FY '27-'28, potentially higher.
- Post FY '27, growth driven by increased product approvals and market expansion, especially in West and East Africa.
- Pune infusion plant ramping up capacity from ~23% to 40-50% utilization in FY '27.
- Expansion in infusion product portfolio to 20-23 products by end of FY '27, exceeding competitors' 12-14.
- Export markets to continue being key revenue drivers, contributing ~77% of total revenue.
2 more points from Sanjivani Paranteral's call on revenue
Create a free account to keep reading this call
MarginsQ3 FY26 call
FlatSee what Sanjivani Paranteral said on margins — free account, 30 seconds.
CapexQ3 FY26 call
Planned- Major capex cycle is currently over; all plants are operational.
- FY '27 capex planned at INR 4 to 4.5 crores, mainly for maintenance, machine upgrades, and software in injectable plants at Mumbai and Dehradun.
- No significant new capex expected in FY '27 beyond this recurring amount.
- Future growth is expected from ramp-up and approvals rather than large new investments.
2 more points from Sanjivani Paranteral's call on capex
Create a free account to keep reading this call
FundraisingQ3 FY26 call
PlannedSee what Sanjivani Paranteral said on fundraising — free account, 30 seconds.
Order bookQ3 FY26 call
- It indicates strong growth driven primarily by export markets and product mix improvements.
- The Pune infusion facility and the Prague-based nutraceutical venture are ramping up, signaling expanding order flow.
- The company expects the infusion facility to have a product portfolio of around 20-23 products by November-December.
- Approval pipelines in West Africa and East Africa are progressing, expected to contribute to growth in FY '27 and FY '28.
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Sanjivani Paranteral latest results (Mar 2026)
Revenue
₹11 Cr
-42% YoY
Net profit
₹1 Cr
-57% YoY
Operating margin
8.66%
EPS
₹0.77
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹3,142 Cr | 34.2 | |
| 2 | 40%+ | Up 2%+ | ₹489 Cr | 16.7 | |
| 3 | 40%+ | Up 0–2% | ₹234 Cr | 17.8 | |
| 4 | 40%+ | Flat | ₹18,464 Cr | 1614.0 | |
| 5 | 40%+ | Flat | ₹9,050 Cr | 34.8 | |
| 6 | 40%+ | Flat | ₹4,493 Cr | — |
Sign up free to see every company in the sector ranking and track Sanjivani Paranteral.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Sanjivani Paranteral
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Sanjivani Paranteral
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 8.12 | 12.58 | 14.00 | 14.96 | 12.86 | 16.44 | 18.13 | 17.35 | 18.18 | 17.89 | 15.50 | 20.86 | 10.51 |
| Expenses + | 6.69 | 10.57 | 11.88 | 12.99 | 10.70 | 14.10 | 15.28 | 14.80 | 15.57 | 15.25 | 13.25 | 17.26 | 9.60 |
| Operating Profit | 1.43 | 2.01 | 2.12 | 1.97 | 2.16 | 2.34 | 2.85 | 2.55 | 2.61 | 2.64 | 2.25 | 3.60 | 0.91 |
| OPM % | 17.61% | 15.98% | 15.14% | 13.17% | 16.80% | 14.23% | 15.72% | 14.70% | 14.36% | 14.76% | 14.52% | 17.26% | 8.66% |
| Other Income + | -0.04 | 0.06 | 0.15 | 0.25 | 0.05 | 0.09 | 0.39 | 0.31 | 0.43 | 0.04 | 0.16 | 0.29 | 0.75 |
| Interest | 0.16 | 0.04 | 0.05 | 0.08 | 0.09 | 0.02 | 0.18 | 0.19 | 0.20 | 0.22 | 0.05 | 0.21 | 0.06 |
| Depreciation | 0.23 | 0.23 | 0.23 | 0.24 | 0.24 | 0.13 | 0.15 | 0.16 | 0.18 | 0.16 | 0.17 | 0.19 | 0.35 |
| Profit before tax | 1.00 | 1.80 | 1.99 | 1.90 | 1.88 | 2.28 | 2.91 | 2.51 | 2.66 | 2.30 | 2.19 | 3.49 | 1.25 |
| Tax % | 0.00% | 13.89% | 14.07% | 13.16% | 33.51% | 24.56% | 21.31% | 24.30% | 17.29% | 24.78% | 25.11% | 24.93% | 25.60% |
| Net Profit + | 1.00 | 1.55 | 1.71 | 1.65 | 1.26 | 1.71 | 2.30 | 1.90 | 2.19 | 1.73 | 1.64 | 2.62 | 0.94 |
| EPS in Rs | 1.00 | 1.55 | 1.71 | 1.65 | 1.08 | 1.46 | 1.97 | 1.60 | 1.84 | 1.43 | 1.34 | 2.13 | 0.77 |
Financials of Sanjivani Paranteral
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 133.03 | 115.31 | 32.53 | 17.96 | 25.09 | 16.29 | 25.09 | 30.59 | 41.45 | 54.41 | 70.10 | 64.76 |
| Expenses + | 127.71 | 120.84 | 55.81 | 70.17 | 26.85 | 16.62 | 22.95 | 24.86 | 35.80 | 46.18 | 59.74 | 55.36 |
| Operating Profit | 5.32 | -5.53 | -23.28 | -52.21 | -1.76 | -0.33 | 2.14 | 5.73 | 5.65 | 8.23 | 10.36 | 9.40 |
| OPM % | 4.00% | -4.80% | -71.56% | -290.70% | -7.01% | -2.03% | 8.53% | 18.73% | 13.63% | 15.13% | 14.78% | 14.52% |
| Other Income + | 1.24 | 0.73 | 2.85 | 0.48 | 0.96 | 0.25 | 0.26 | 0.24 | 0.54 | 0.52 | 1.21 | 1.24 |
| Interest | 7.92 | 8.81 | 4.79 | 0.45 | 0.33 | 0.66 | 0.13 | 0.21 | 0.36 | 0.25 | 0.59 | 0.54 |
| Depreciation | 1.41 | 1.36 | 1.20 | 1.19 | 1.17 | 1.07 | 0.86 | 0.88 | 0.89 | 0.93 | 0.62 | 0.86 |
| Profit before tax | -2.77 | -14.97 | -26.42 | -53.37 | -2.30 | -1.81 | 1.41 | 4.88 | 4.94 | 7.57 | 10.36 | 9.24 |
| Tax % | -13.00% | -2.20% | -0.72% | -0.60% | -10.00% | -5.52% | -0.71% | 0.61% | 8.70% | 18.63% | 21.81% | 25.00% |
| Net Profit + | -2.41 | -14.64 | -26.22 | -53.06 | -2.07 | -1.71 | 1.42 | 4.85 | 4.51 | 6.17 | 8.10 | 6.92 |
| EPS in Rs | -4.09 | -24.82 | -44.45 | -89.96 | -3.51 | -2.90 | 1.67 | 4.85 | 4.51 | 5.28 | 6.82 | 5.63 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 7.33% | 0.00% |
Financials of Sanjivani Paranteral
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.90 | 5.90 | 5.90 | 5.90 | 5.90 | 5.90 | 8.50 | 10.00 | 10.00 | 11.68 | 11.88 | 12.28 |
| Reserves | 26.24 | 11.60 | -14.62 | -58.72 | -53.10 | -54.81 | -53.39 | -17.58 | -13.07 | 16.22 | 26.12 | 32.55 |
| Borrowings + | 57.06 | 62.20 | 59.89 | 48.23 | 48.09 | 48.91 | 46.05 | 6.00 | 2.49 | 0.97 | 5.62 | 6.70 |
| Other Liabilities + | 24.48 | 13.42 | 9.15 | 29.61 | 17.09 | 15.66 | 18.11 | 19.87 | 21.59 | 14.53 | 21.37 | 6.85 |
| Total Liabilities | 113.68 | 93.12 | 60.32 | 25.02 | 17.98 | 15.66 | 19.27 | 18.29 | 21.01 | 43.40 | 64.99 | 58.38 |
| Fixed Assets + | 13.52 | 12.69 | 11.19 | 10.17 | 8.99 | 8.04 | 7.62 | 7.42 | 7.57 | 9.94 | 20.56 | 21.28 |
| CWIP | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.00 | 3.00 | 3.91 |
| Other Assets + | 100.10 | 80.38 | 49.08 | 14.80 | 8.94 | 7.57 | 11.60 | 10.82 | 13.39 | 33.46 | 41.43 | 33.19 |
| Total Assets | 113.68 | 93.12 | 60.32 | 25.02 | 17.98 | 15.66 | 19.27 | 18.29 | 21.01 | 43.40 | 64.99 | 58.38 |
Financials of Sanjivani Paranteral
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -1.20 | 0.45 | 9.57 | 3.05 | 2.48 | -0.17 | 0.58 | 8.52 | 4.68 | -10.70 | -0.24 | -1.55 |
| Cash from Investing Activity + | 8.68 | -0.50 | 0.30 | -0.20 | 0.02 | -0.12 | -0.42 | -0.67 | -0.99 | -12.21 | -5.81 | -4.47 |
| Cash from Financing Activity + | -7.30 | -0.51 | -10.05 | -2.83 | -2.30 | 0.33 | -0.26 | -7.68 | -3.73 | 23.16 | 6.14 | 6.54 |
| Net Cash Flow | 0.18 | -0.57 | -0.18 | 0.03 | 0.20 | 0.03 | -0.09 | 0.17 | -0.04 | 0.24 | 0.09 | 0.52 |
| Free Cash Flow | 7.47 | -0.06 | 9.87 | 2.85 | 2.50 | -0.30 | 0.15 | 7.84 | 3.63 | -14.00 | -11.48 | -5.21 |
| CFO/OP | -23% | -8% | -41% | -6% | -143% | 48% | 28% | 150% | 84% | -117% | 10% | 6% |
Financials of Sanjivani Paranteral
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 184.24 | 151.59 | 358.38 | 107.71 | 75.79 | 23.97 | 96.45 | 58.71 | 17.52 | 31.53 | 86.85 | |
| Inventory Days | 68.59 | 65.35 | 127.41 | 34.08 | 13.56 | 66.80 | 22.43 | 51.89 | 105.21 | 124.70 | 93.96 | |
| Days Payable | 37.50 | 19.51 | 42.51 | 169.13 | 292.82 | 434.62 | 261.00 | 339.20 | 269.82 | 73.56 | 137.51 | |
| Cash Conversion Cycle | 215.34 | 197.43 | 443.28 | -27.33 | -203.47 | -343.84 | -142.12 | -228.61 | -147.08 | 82.67 | 43.30 | |
| Working Capital Days | 61.38 | 26.72 | -196.58 | -1,285.22 | -714.43 | -1,162.44 | -707.31 | -173.01 | -129.27 | 35.55 | 83.73 | |
| ROCE % | 5.95% | -7.31% | -35.52% | -227.18% | -258.43% | 265.52% | 55.28% | 30.21% |
Guidance history
How Sanjivani Paranteral's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q3 FY26 call → | 10–20% | Flat | Planned | Planned | — |
| Q2 FY26 call → | 10–20% | Flat | Planned | Planned | Rising |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Sanjivani Paranteral: frequently asked questions
What is Sanjivani Paranteral share price today?
Sanjivani Paranteral last traded at ₹166.8, with a market capitalisation of ₹205 Cr and a P/E ratio of 20.6.
What were Sanjivani Paranteral's latest quarterly results?
For the quarter ended Mar 2026, Sanjivani Paranteral reported revenue of ₹11 Cr (-42% year on year) and net profit of ₹1 Cr, with an operating margin of 8.66%.
Is Sanjivani Paranteral's profit growing?
Net profit was ₹1 Cr in Mar 2026 against ₹2 Cr in Mar 2025, a change of -57%.
What is Sanjivani Paranteral's EPS?
Sanjivani Paranteral's earnings per share for the quarter ended Mar 2026 was ₹0.77.
What is Sanjivani Paranteral's ROE and ROCE?
Sanjivani Paranteral's return on equity is 18.2% and its return on capital employed is 22.4%.
Does Sanjivani Paranteral pay a dividend?
Yes. Sanjivani Paranteral's dividend yield is 0.32% at the current price. The full payout history is on the Sanjivani Paranteral dividends page.
Which sector does Sanjivani Paranteral belong to?
Sanjivani Paranteral is in the Pharmaceuticals & Biotechnology sector. Its peer comparison and sector ranking are on this page.
What did Sanjivani Paranteral's management say on the latest earnings call?
Arthneeti's analysis of the Q1 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Sanjivani Paranteral's management.
How does Arthneeti AI analyse Sanjivani Paranteral?
Arthneeti reads Sanjivani Paranteral's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.
Continue your research
What Sanjivani Paranteral's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem
